{"id":"NCT00130533","sponsor":"Spanish Breast Cancer Research Group","briefTitle":"Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients","officialTitle":"Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Capecitabine Following Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2017-02-17","completion":"2017-02-17","firstPosted":"2005-08-15","resultsPosted":"2019-10-25","lastUpdate":"2023-03-31"},"enrollment":876,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]}],"arms":[{"label":"Xeloda (capecitabine)","type":"EXPERIMENTAL"},{"label":"Observation","type":"NO_INTERVENTION"}],"summary":"This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.","primaryOutcome":{"measure":"Disease Free Survival (DFS) Events","timeFrame":"5 years","effectByArm":[{"arm":"Xeloda (Capecitabine)","deltaMin":105,"sd":null},{"arm":"Observation","deltaMin":120,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":18,"exclusionCount":18},"locations":{"siteCount":48,"countries":["Spain"]},"refs":{"pmids":["31804894","33397968","36346687","35279130"],"seeAlso":["http://www.ciboma.org/","http://www.geicam.org/"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":436},"commonTop":["FATIGUE","LEUKOCYTES (TOTAL WBC)","RASH: HAND-FOOT SKIN REACTION","HEMOGLOBIN","IRREGULAR MENSES"]}}